Back to search

Article

Post-Percutaneous Coronary Intervention CYP2C19 Genotyping: The Potential Role In Identifying Clopidogrel Therapy Related Bleeding Risks

2023-01-10

Abstract excerpt

<h4>Aim: </h4> Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains the standard of care. CYP2C19 genetic polymorphisms results in variable Clopidogrel bioactivation. Increased function (CYP2C19*17) allele carriers (rapid metabolizers (RM) or ultrarapid metabolizers (UM)), are Clopidogrel hyper-responders and hence more susceptible to Clopidogrel related bleeding. Since current g...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bc7e9d88-2002-5605-b62e-32b416360e8d
DOI
10.22541/au.167335794.41861576/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Post-Percutaneous Coronary Intervention CYP2C19 Genotyping: The Potential Role In Identifying Clopidogrel Therapy Related Bleeding RisksDOI 10.22541/au.167335794.41861576/v1
Post-percutaneous coronary intervention CYP2C19 genotyping in an Irish population: The potential role in identifying clopidogrel therapy-related bleeding risks.Semantic proximity
CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Semantic proximity
Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping.Semantic proximity
Genetic variation in activating clopidogrel: longer-term outcomes in a large community cohortSemantic proximity
Pharmacogenetics at scale in real-world bioresources: CYP2C19 and clopidogrel outcomes in UK Biobank.Semantic proximity
Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure.Semantic proximity
CYP2C19 genotype-directed P2Y12 inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention.Semantic proximity
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.Semantic proximity
Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity
Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation.Semantic proximity
Select a neighboring publication to make it the new centre.